James Bylund - 03 Mar 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Chief Operating Officer
Signature
/s/ Marc Baumgartner (Attorney in Fact)
Issuer symbol
RGEN
Transactions as of
03 Mar 2025
Net transactions value
-$192,516
Form type
4
Filing time
04 Mar 2025, 13:29:29 UTC
Previous filing
28 Feb 2025
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +6,435 +34% $0.000000 25,198 03 Mar 2025 Direct F1
transaction RGEN Common Stock Tax liability $192,516 -1,239 -4.9% $155.38 23,959 03 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +6,056 $0.000000 6,056 03 Mar 2025 Common Stock 6,056 $155.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Bylund was awarded 6,435 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
F3 One third of the stock options will vest and become exercisable annually on March 3, 2026, March 3, 2027, and March 3, 2028.